Weight

Ozempic, Wegovy and other GLP-1 drugs are being investigated as treatments for many health conditions—from dementia to addiction to kidney problems

The neurons that produce a sick feeling and food aversion are distinct from those that induce a feeling of fullness

As the patents on various weight-loss drugs near expiration, companies in India and China are vying to make lower-cost versions that will widen access to such treatments

Semaglutide, the same compound in obesity drug Wegovy, slashes risk of kidney failure and death for people with type 2 diabetes

Many researchers think that Wegovy and Ozempic should be taken for life, but myriad factors can force people off the drugs

The FDA recently approved semaglutide (Wegovy) for preventing serious heart conditions in some people, but questions remain about how it works

A plethora of new weight-loss drugs are now available in the U.S., but they aren’t necessarily the same. Here’s a guide to the latest GLP-1 receptor agonists

Popular weight-loss and diabetes drugs, such as Ozempic and Wegovy, target metabolic pathways that gut microbes and food molecules already play a key role in regulating

The world has launched into an era of injectables not just to treat obesity but to manage weight. Is that all good news?

Studies of goal setting reveal why it’s so hard to keep resolutions—and how to make ones that actually stick

Ozempic and similar drugs are ushering in a new era of weight management and obesity treatments, and researchers are racing to understand their impact

From new uses for weight-loss drugs to the first CRISPR gene editing therapy, these were some of the most impactful health stories of the year